Comparative Pharmacology
Head-to-head clinical analysis: LIBRITABS versus OXAZEPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIBRITABS versus OXAZEPAM.
LIBRITABS vs OXAZEPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Libritabs (chlordiazepoxide) is a benzodiazepine that binds to GABA-A receptors at the gamma subunit, potentiating GABAergic inhibition and producing anxiolytic, sedative, and anticonvulsant effects.
Binds to GABA-A receptor at benzodiazepine binding site, enhancing Cl- ion conductance and increasing inhibitory neurotransmission. Anxiolytic, sedative, hypnotic, anticonvulsant, and muscle relaxant effects.
5-10 mg orally 3-4 times daily; up to 30 mg/day in divided doses for severe anxiety.
10-30 mg orally 3-4 times daily; maximum 120 mg/day.
None Documented
None Documented
Terminal elimination half-life is 15-20 hours; clinical context: steady-state reached in 3-5 days with daily dosing, prolonged in hepatic impairment.
Clinical Note
moderateOxazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Oxazepam is combined with Fluticasone propionate."
Clinical Note
moderateOxazepam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Oxazepam."
Clinical Note
moderateOxazepam + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Oxazepam."
Clinical Note
moderateOxazepam + Cyclosporine
Terminal elimination half-life is 5-15 hours (mean 8 hours); no active metabolites, thus accumulation is minimal even with repeated dosing.
Renal: 70-80% as unchanged drug and glucuronide conjugate; fecal: 15-20% via biliary elimination.
Renal (primarily as glucuronide conjugates, with less than 1% unchanged); biliary/fecal excretion is minimal.
Category C
Category D/X
Benzodiazepine
Benzodiazepine
"The metabolism of Cyclosporine can be decreased when combined with Oxazepam."